UnitedHealth Group is initiated with a Strong Buy rating and a $533 price target, suggesting 33% upside from its current price. The positive outlook is driven by margin recovery, Optum Health's move to higher-quality contracts, and AI-enhanced efficiencies expected to support double-digit earnings growth through 2028. The stock trades below the healthcare sector median valuation, with adjusted EPS projected to rise from $20.5 in 2026 to $26.41 in 2028. Risks include higher medical usage, regulatory scrutiny, and Medicare Advantage quality ratings, but the earnings outlook supports a favorable risk-reward profile.
UnitedHealth Group shares are trading at USD 419.59 on Pluang as of Oct 21, 2026 02:21 WIB, showing a 3.12% gain in the last day. The stock's market capitalization stands at $365.21 billion, reflecting its significant presence in the health sector. Investor sentiment on Pluang leans bullish with 73% of orders to buy, aligning with the positive outlook in the news.
UnitedHealth Group was downgraded from strong buy to buy because its shares appear fully valued at a 20x forward price-to-earnings ratio. The company reported better-than-expected Q3 earnings with revenue of $112.7 billion and earnings per share of $...
UnitedHealth's stock price fell 51.32% from November 2024 to May 2025, then rose 40.64% by October 2026. These price moves directly influenced its weighting in the SPDR Dow Jones Industrial Average ETF (DIA), which is price-weighted. This means the f...
